Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for D&D Pharmatech Inc. (347850:KRX), powered by AI.
D&D Pharmatech Inc. is currently trading at ₩70,800. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for D&D Pharmatech Inc. on Alpha Lenz.
D&D Pharmatech Inc.'s P/E ratio is -131.7.
“D&D Pharmatech Inc. trades at a P/E of -131.7 (undervalued) with modest ROE of -31.5%. 3Y revenue CAGR of 91.6% highlights clear growth momentum.”
Ask for details →D&D Pharmatech Inc. is a biotechnology company dedicated to the development and commercialization of innovative therapeutic solutions. The company primarily focuses on advancing treatments for central nervous system disorders, metabolic diseases, and fibrotic diseases, with a robust pipeline of drug candidates in various stages of clinical trials. Utilizing cutting-edge scientific research and strategic partnerships, D&D Pharmatech aims to address unmet medical needs, enhancing the lives of patients while contributing to advancements in medical science. With operations that span drug discovery to clinical development, the company plays a significant role in the biotechnology sector, impacting both healthcare providers and patients. By leveraging proprietary technology platforms, D&D Pharmatech is positioned at the forefront of biopharmaceutical innovation, reinforcing its commitment to driving transformative medicine. Its contributions to the biotech industry are marked by a strong emphasis on research and development, exemplifying the dynamic nature of the sector and its potential to disrupt traditional treatment paradigms.
“D&D Pharmatech Inc. trades at a P/E of -131.7 (undervalued) with modest ROE of -31.5%. 3Y revenue CAGR of 91.6% highlights clear growth momentum.”
Ask for details →D&D Pharmatech Inc. (ticker: 347850) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 21 employees. Market cap is $3.1T.
The current price is ₩70,800 with a P/E ratio of -131.67x and P/B of 39.01x.
ROE is -31.49% and operating margin is -790.97%. Annual revenue is $4.3B.